Anthem BCBS GLP-1 coverage: PA criteria, formulary tiers, and 2026 plan rules

Anthem Blue Cross Blue Shield — one of the largest BCBS licensees, operating in California, Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri, Nevada, New Hampshire, New York, Ohio, Virginia, and Wisconsin — covers GLP-1 receptor agonists across commercial, Medicaid, and Medicare plans, but coverage rules differ sharply by state, line of business, and employer benefit design. In 2025–2026, Anthem tightened weight-loss GLP-1 criteria on several formularies, removed Wegovy and Zepbound from weight-loss coverage on many fully insured plans, and introduced updated prior authorization (PA) policies that raise the bar for new starts.

This guide maps which GLP-1 medications Anthem covers under which diagnoses, details PA criteria and step therapy requirements for each line of business, explains common denial reasons, and provides a plan-by-plan coverage summary. It is independent information and not medical advice or reimbursement guidance for a specific patient or plan.

Quick answer

Key policy dates:

• January 1, 2025: Anthem California reclassified all GLP-1 drugs from Tier 3 non-formulary to Tier 4 specialty drugs; they remain non-formulary and require PA

• January 1, 2026: Many Anthem plans removed Wegovy from formulary for weight-loss coverage; some employer-sponsored plans still include it via optional rider

• 2026 (ongoing): Anthem multi-state plans expanding GLP-1 access for cardiovascular and MASH indications per updated FDA labeling for Wegovy

Who this is for

• Anthem commercial members and their prescribers navigating GLP-1 prior authorization

• Anthem Medicaid members in covered states

• Benefit verification specialists and hub teams handling Anthem pharmacy claims

• Market access teams at GLP-1 manufacturers tracking Anthem BCBS policy changes

• Employer benefits administrators evaluating Anthem GLP-1 coverage options

Anthem structure and why it matters for GLP-1

Anthem is the trade name used by Elevance Health (formerly Anthem, Inc.) for its Blue Cross Blue Shield licensed plans. Each Anthem BCBS plan operates somewhat independently within its state, meaning GLP-1 coverage rules can vary between California, Virginia, New York, and other states. The key Anthem entities include:

• Anthem Blue Cross (California): Largest Anthem entity; reclassified GLP-1s to Tier 4 specialty in 2025

• Anthem Blue Cross and Blue Shield: Multi-state operation across Connecticut, Indiana, Kentucky, and others

• Anthem Blue Cross Blue Shield (Georgia, Virginia, and others): State-specific formularies and PA criteria

For prescribers and market access teams, the critical implication is that a prior authorization that succeeds in one Anthem state may be denied in another, even within the same employer group.

Type 2 diabetes GLP-1 coverage

Covered medications and tier placement

Anthem covers the following GLP-1 medications for type 2 diabetes across most plans:

PA criteria for T2D

Anthem's standard PA criteria for GLP-1 receptor agonists prescribed for type 2 diabetes typically require:

1. Diagnosis confirmation: Documented type 2 diabetes diagnosis verified by one of:

   • HbA1c ≥ 6.5%

   • Fasting plasma glucose ≥ 126 mg/dL

   • Two-hour plasma glucose ≥ 200 mg/dL on OGTT

   • Symptoms of hyperglycemia with random plasma glucose ≥ 200 mg/dL

2. Step therapy: Trial and failure (or contraindication) of metformin or other first-line therapy

3. Dose limits: Must not exceed FDA-approved maximum dose

4. Concurrent therapy: GLP-1 receptor agonists should not be prescribed concurrently with other GLP-1 agents

5. Approval duration: Typically 12 months

Anthem's PA form for GLP-1 agents confirms that weight loss is excluded under the CMS exclusion for Medicare plans and that the diagnosis restriction applies (source: Anthem provider PA criteria documentation).

Weight-loss GLP-1 coverage

Employer-sponsored plans (commercial group)

Weight-loss GLP-1 coverage under Anthem commercial plans depends heavily on the specific employer group:

• Large employer groups (>100 employees): Some plans include a weight-loss drug rider that covers Wegovy, Zepbound, or Saxenda. The employer must elect this optional coverage

• Small employer groups (<100 employees): Weight-loss GLP-1 coverage is generally excluded from standard formularies; optional riders may not be available

• Self-funded plans: The employer determines coverage directly; Anthem administers the plan per employer instructions

PA criteria for weight loss (when covered)

When an Anthem plan does cover weight-loss GLP-1 medications, the PA criteria typically include:

1. BMI threshold: BMI ≥ 30 kg/m², or BMI ≥ 27 kg/m² with at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea)

2. Lifestyle documentation: Participation in a structured weight-loss program for at least 3–6 months, including reduced-calorie diet, increased physical activity, and behavioral modification

3. Step therapy: Trial and failure of at least one older weight-loss medication (phentermine, Contrave, Qsymia, orlistat) unless contraindicated

4. Prescriber attestation: That the member is receiving standard-of-care management for weight-related conditions

5. Initial authorization: Typically 6 months; renewal requires documentation of ≥ 5% body weight reduction

Individual and marketplace plans

Anthem individual and Affordable Care Act marketplace plans generally do not cover GLP-1 medications for weight loss. KFF research confirmed that ACA marketplace plans rarely cover GLP-1 drugs approved solely for obesity treatment — Wegovy was covered by just 1% of marketplace prescription drug plans, while Ozempic (same active ingredient, approved for diabetes) was covered by 82% (source: KFF, June 2024).

This pattern holds for Anthem marketplace plans across most states. GLP-1 coverage is limited to type 2 diabetes treatment.

Weight-loss exclusion

Many Anthem fully insured plans have a weight-loss exclusion that categorically denies coverage for medications prescribed primarily for weight management. Key details:

• This is a benefit exclusion, not a formulary decision — it cannot be appealed as a medical necessity determination

• Some plans allow GLP-1 coverage for FDA-approved non-weight-loss indications (cardiovascular risk reduction with Wegovy, obstructive sleep apnea with Zepbound)

• The exclusion applies regardless of BMI, comorbidities, or prior authorization approval

State-by-state variation

Anthem BCBS plans vary by state. Here are notable differences as of mid-2026:

California-specific detail

Anthem Blue Cross (California) provides a detailed illustration of Anthem's GLP-1 trend:

• As of January 1, 2025, all GLP-1 drugs were reclassified from Tier 3 non-formulary to Tier 4 specialty drugs. They remain non-formulary and still require prior authorization

• Previously, Anthem provided coverage by overriding the plan exclusion when GLP-1 drugs gained popularity. Starting around October 2024, claims began to be denied correctly as an exclusion

• Even for non-obesity indications, authorization is still required

Source: Word & Brown General Agency, updated May 1, 2026.

Medicare and Medicaid

Anthem Medicare Advantage

Anthem Medicare Advantage plans cover GLP-1 medications for type 2 diabetes with prior authorization. Weight-loss GLP-1 coverage follows CMS rules — Medicare Part D does not cover drugs for weight loss. However:

• Wegovy may be covered for cardiovascular risk reduction in patients with established cardiovascular disease and obesity

• Wegovy may be covered for MASH (metabolic dysfunction-associated steatohepatitis) per updated FDA labeling

• The CMS Medicare GLP-1 Bridge demonstration may expand access starting July 2026

Anthem Medicaid

Anthem administers Medicaid managed care plans in select states. GLP-1 coverage follows state Medicaid rules:

• GLP-1s for type 2 diabetes: covered with PA in most states

• GLP-1s for weight loss: generally not covered or very limited; some states may cover under specific criteria

• EPSDT benefit for members under 21 may provide coverage in some circumstances

New indications and emerging coverage

Wegovy for MASH

The FDA approved Wegovy for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH). Anthem is updating coverage criteria to include this indication:

• Biopsy-confirmed MASH with F2–F3 fibrosis, or imaging-based biomarker confirmation

• Prescribed by or in consultation with a hepatologist or gastroenterologist

• Coverage applies even on plans where weight-loss GLP-1 is excluded, because MASH is a separate diagnosis

Wegovy for cardiovascular risk reduction

Wegovy's cardiovascular indication (reduction of major adverse cardiovascular events in adults with established CVD and obesity) is increasingly covered:

• Medicare Part D plans: covered per CMS guidance

• Commercial plans: covered on many Anthem plans even when weight-loss GLP-1 is excluded

• PA criteria: documented cardiovascular disease plus BMI ≥ 27 kg/m²

Zepbound for obstructive sleep apnea

The FDA approved Zepbound for obstructive sleep apnea (OSA) in adults with obesity. Anthem coverage:

• Covered on some commercial plans as a non-weight-loss indication

• PA criteria require documented OSA diagnosis and continued symptoms despite positive airway pressure therapy

• Coverage varies by plan; verify benefits before prescribing

Common denial reasons and appeal steps

Top denial reasons

1. Weight-loss exclusion: The plan has a categorical benefit exclusion for weight-loss medications — this is the most common denial

2. Missing diabetes documentation: For T2D GLP-1 requests, failure to provide A1C, FPG, or OGTT results confirming diabetes diagnosis

3. Step therapy not met: Patient has not tried and failed preferred GLP-1 agents or older weight-loss medications

4. BMI below threshold: Patient does not meet BMI ≥ 30 (or ≥ 27 with comorbidity) criteria

5. Incomplete lifestyle documentation: Missing documentation of structured weight-loss program participation

6. Concurrent GLP-1 use: Patient is already on another GLP-1 receptor agonist

Appeal workflow

1. Gather documentation: Ensure all clinical records, lab results, BMI documentation, lifestyle program records, and prior medication trials are documented

2. Peer-to-peer review: Request a peer-to-peer review with Anthem's medical director; this is often the most effective step

3. External review: If internal appeal is denied, request an independent external review (available for most commercial plans)

4. Exception request: For employer plans, the benefits administrator may be able to request a plan-level exception

Reauthorization criteria

When GLP-1 coverage is initially approved, Anthem typically requires reauthorization:

Prescribing checklist

Before submitting a GLP-1 prior authorization to Anthem:

• Confirm the patient's specific Anthem plan and state of residence

• Verify whether the plan includes a weight-loss drug rider (for Wegovy/Zepbound)

• Document BMI with date and clinical setting

• Document diabetes diagnosis with lab results (A1C, FPG, or OGTT) if T2D indication

• Record prior medication trials (metformin, other GLP-1s, older weight-loss drugs)

• Document participation in structured lifestyle program (3–6 months minimum)

• Confirm prescriber specialty requirements (hepatologist for MASH, etc.)

• Submit via CoverMyMeds or Anthem's provider portal

What to monitor

• Anthem formulary updates: Anthem updates formularies quarterly; check for tier changes and PA criteria updates

• State legislation: Several states are considering mandates for GLP-1 obesity coverage, which could override Anthem plan exclusions

• CMS Medicare GLP-1 Bridge: Expected to expand Medicare coverage for GLP-1 weight-loss drugs starting mid-2026

• Wegovy HD (7.2 mg): FDA approved March 19, 2026 — may affect formulary placement and PA criteria as plans update tier assignments

• Employer open enrollment: Weight-loss GLP-1 rider availability changes during annual enrollment periods

Sources

• Anthem Blue Cross California, GLP-1 Coverage Considerations, November 2025: https://providers.anthem.com/docs/gpp/california-provider/CA_MMP_GLP1Coverage.pdf

• Anthem Provider News, Glucagon-Like Peptide-1 Prior Authorization Changes: https://providernews.anthem.com/california/articles/glucagon-like-peptide-1-prior-authorization-changes-16845-16893

• Word & Brown General Agency, Weight Loss Drugs (GLP-1) Insurance Coverage Breakdown, updated May 1, 2026: https://www.wordandbrown.com/NewsPost/Weight-Loss-Drugs-(GLP-1)-Coverage

• KFF, Costly GLP-1 Drugs are Rarely Covered for Weight Loss by Marketplace Plans, June 2024: https://www.kff.org/affordable-care-act/costly-glp-1-drugs-are-rarely-covered-for-weight-loss-by-marketplace-plans

• KFF, Medicaid Coverage of and Spending on GLP-1s: https://www.kff.org/medicaid/medicaid-coverage-of-and-spending-on-glp-1s

• FDA, Wegovy (semaglutide) prescribing information and FDA-approved indications: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215256s011s012s013s014lbl.pdf

• Anthem Virginia Prior Authorization Form, Weight-Loss Management: https://providers.anthem.com/docs/gpp/VA_CAID_WeightLossMgmtPAForm.pdf

• Prime Therapeutics, GLP-1 Pipeline Update, February 2026: https://www.primetherapeutics.com/glp-1-pipeline-update-february-2026